PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.

Abstract Congenital malformations might occur because of environmental or genetic factors, and sometimes occur because of unknown causes. Acetazolamide is a carbonic anhydrase inhibitor that is used to treat idiopathic intracranial hypertension, glaucoma, and epilepsy. The use of acetazolamide has not been recommended for pregnant women because of reported teratogenic risks. Congenital malformations, such as ectrodactyly, syndactyly, cleft lip/palate, and retarded incisor teeth development, have been reported in experimental animals. However, tooth agenesis due to the use of acetazolamide has not been reported yet. Oligodontia is a severe type of tooth agenesis involving six or more congenitally missing teeth. The causes of oligodontia are attributed to environmental factors, such as irradiation, drugs, trauma, tumors, infection, genetic factors, or a combination. There is no credible evidence of undesirable effects of acetazolamide use in human pregnancy. However, we report a case of a 12-year-old Saudi boy who was exposed to maternal acetazolamide (1,000 mg/day) for treatment of idiopathic intracranial hypertension before pregnancy, during the first trimester, and throughout the pregnancy. This treatment might have resulted in some congenital malformations, such as ectrodactyly, syndactyly, and oligodontia.
PMID
Related Publications

Acetazolamide for the treatment of idiopathic intracranial hypertension.

Idiopathic intracranial hypertension and pregnancy.

The Idiopathic Intracranial Hypertension Treatment Trial: A Long-Time Coming but Worth the Wait.

The use of acetazolamide in idiopathic intracranial hypertension during pregnancy.

The use of acetazolamide during pregnancy in intracranial hypertension patients.

Authors

Mayor MeshTerms
Keywords

acetazolamide

ectrodactyly

oligodontia

syndactyly

Journal Title drug design, development and therapy
Publication Year Start




PMID- 27143854
OWN - NLM
STAT- MEDLINE
DA  - 20160504
DCOM- 20161230
LR  - 20161231
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Possible association between acetazolamide administration during pregnancy and
      multiple congenital malformations.
PG  - 1471-6
LID - 10.2147/DDDT.S99561 [doi]
AB  - Congenital malformations might occur because of environmental or genetic factors,
      and sometimes occur because of unknown causes. Acetazolamide is a carbonic
      anhydrase inhibitor that is used to treat idiopathic intracranial hypertension,
      glaucoma, and epilepsy. The use of acetazolamide has not been recommended for
      pregnant women because of reported teratogenic risks. Congenital malformations,
      such as ectrodactyly, syndactyly, cleft lip/palate, and retarded incisor teeth
      development, have been reported in experimental animals. However, tooth agenesis 
      due to the use of acetazolamide has not been reported yet. Oligodontia is a
      severe type of tooth agenesis involving six or more congenitally missing teeth.
      The causes of oligodontia are attributed to environmental factors, such as
      irradiation, drugs, trauma, tumors, infection, genetic factors, or a combination.
      There is no credible evidence of undesirable effects of acetazolamide use in
      human pregnancy. However, we report a case of a 12-year-old Saudi boy who was
      exposed to maternal acetazolamide (1,000 mg/day) for treatment of idiopathic
      intracranial hypertension before pregnancy, during the first trimester, and
      throughout the pregnancy. This treatment might have resulted in some congenital
      malformations, such as ectrodactyly, syndactyly, and oligodontia.
FAU - Al-Saleem, Afnan I
AU  - Al-Saleem AI
AD  - Dental Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
FAU - Al-Jobair, Asma M
AU  - Al-Jobair AM
AD  - Department of Pediatric Dentistry and Orthodontics, College of Dentistry, King
      Saud University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160415
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - O3FX965V0I (Acetazolamide)
RN  - Ectrodactyly
SB  - IM
CIN - Drug Des Devel Ther. 2016 Nov 10;10 :3681-3683. PMID: 27877019
MH  - Abnormalities, Multiple/*chemically induced
MH  - Acetazolamide/administration & dosage/*adverse effects/*therapeutic use
MH  - Child
MH  - Female
MH  - Humans
MH  - Limb Deformities, Congenital/chemically induced
MH  - Male
MH  - Preconception Injuries/*chemically induced
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pseudotumor Cerebri/*drug therapy
MH  - Syndactyly/chemically induced
PMC - PMC4841426
OID - NLM: PMC4841426
OTO - NOTNLM
OT  - acetazolamide
OT  - ectrodactyly
OT  - oligodontia
OT  - syndactyly
EDAT- 2016/05/05 06:00
MHDA- 2016/12/31 06:00
CRDT- 2016/05/05 06:00
AID - 10.2147/DDDT.S99561 [doi]
AID - dddt-10-1471 [pii]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Apr 15;10:1471-6. doi: 10.2147/DDDT.S99561. eCollection
      2016.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>